Dr. Gilchuk received his M.S. in biochemistry, and doctorate in Biotechnology in 2007 from National Taras Shevchenko University of Kyiv, (Kyiv, Ukraine). His dissertation was focused on generation of mouse single-chain antibodies and their application for affinity purification of target proteins. After graduation Dr. Gilchuk was working on both research and developmental projects, as a researcher and later as a group leader. From 2002 to 2009 Dr. Gilchuk was hired by former Phage Biotechnology Corporation (San Diego, CA) where he was advanced from Engineer Biologist to Research Group Manager. As a part of his effort Dr. Gilchuk also occupied a staff scientist position at the Institute of Molecular Biology and Genetics NASU (Kyiv, Ukraine), and served as the laboratory head at the State Institute of Genetic and Regenerative Medicine AMSU (Kyiv, Ukraine). This work resulted in four Ukrainian declarative and one US inventory patents (U.S. Patent Number: 7,435,804), as well as 11 primary research publications. In 2009 Dr. Gilchuk joined Dr. Joyce’s laboratory at Vanderbilt University where he was involved in several projects. These projects were focused on a large scale vaccinia virus-derived T cell epitope discovery (N01-AI-40079), elucidation of immunological properties of lung-resident memory CD8 T cells (Mini-Sabbatical Award, Program in Immunology at Vanderbilt), and development the technological platforms for T cell-targeted mucosal vaccination (AI042284). His work resulted in nine primary research publications, two reviews, and one book chapter. In 2016, Dr. Gilchuk joined the Crowe Lab as staff scientist and will study human antibody-mediated immunity against filoviruses. Dr. Gilchuk is a member of the American Association of Immunologists.